Clinical Research Directory

Inclusion Criteria: * Signed informed consent form. * Age ≥18 years. Gender is not limited. * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2. * Participants with relapsed or refractory multiple myeloma (RRMM) who have received 1 to 3 prior lines of therapy, including at least one proteasome inhibitor and one immunomodulatory drug. * Investigator-assessed evidence of disease progression or failure to achieve response after the last line of therapy, according to the International Myeloma Working Group (2016IMWG) criteria. * Measurable disease at screening, defined by at least one of the following: 1. Serum M-protein≥5 g/L; 2. Urine M-protein≥200 mg/24 h; 3. Involved serum FLC level≥100 mg/L with an abnormal κ/λ ratio. Exclusion Criteria: * Received any prior B cell maturation antigen (BCMA)-targeted therapy. * IMWG-defined disease refractory to anti-CD38 therapy. * Participants are not eligible to receive DPd as control therapy if any of the following are present: Contraindication, life-threatening hypersensitivity, or intolerance to pomalidomide. * Participants with primary light-chain amyloidosis (AL), plasma cell leukemia, Waldenström macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or solitary plasmacytoma. * Received a cumulative dose of corticosteroids equivalent to ≥140 mg of prednisone within 14 days before randomization. * Received a live, attenuated vaccine within 4 weeks before randomization. * Contraindication, intolerance, or life-threatening allergy to any investigational product or excipient.